CA2109598A1 - Methodes therapeutiques et diagnostiques basees sur l'expression de la neurotrophine 4 - Google Patents

Methodes therapeutiques et diagnostiques basees sur l'expression de la neurotrophine 4

Info

Publication number
CA2109598A1
CA2109598A1 CA002109598A CA2109598A CA2109598A1 CA 2109598 A1 CA2109598 A1 CA 2109598A1 CA 002109598 A CA002109598 A CA 002109598A CA 2109598 A CA2109598 A CA 2109598A CA 2109598 A1 CA2109598 A1 CA 2109598A1
Authority
CA
Canada
Prior art keywords
ser
arg
thr
val
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002109598A
Other languages
English (en)
Inventor
Finn Hallbook
Carlos F. I. Moliner
Hakan B. Persson
Nancy Ip
George D. Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
HALBOOK FINN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HALBOOK FINN filed Critical HALBOOK FINN
Publication of CA2109598A1 publication Critical patent/CA2109598A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Toys (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002109598A 1991-05-21 1992-05-20 Methodes therapeutiques et diagnostiques basees sur l'expression de la neurotrophine 4 Abandoned CA2109598A1 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US70345091A 1991-05-21 1991-05-21
US703,450 1991-05-21
US72925391A 1991-07-12 1991-07-12
US729,253 1991-07-12
US73442291A 1991-07-23 1991-07-23
US734,422 1991-07-23
US75135691A 1991-08-28 1991-08-28
US751,356 1991-08-28
US76267491A 1991-09-20 1991-09-20
US762,674 1991-09-20
US79192491A 1991-11-14 1991-11-14
US791,924 1991-11-14

Publications (1)

Publication Number Publication Date
CA2109598A1 true CA2109598A1 (fr) 1992-11-26

Family

ID=27560239

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002109598A Abandoned CA2109598A1 (fr) 1991-05-21 1992-05-20 Methodes therapeutiques et diagnostiques basees sur l'expression de la neurotrophine 4

Country Status (8)

Country Link
EP (1) EP0587806A4 (fr)
JP (1) JPH08510987A (fr)
AU (1) AU674659B2 (fr)
CA (1) CA2109598A1 (fr)
IE (1) IE921636A1 (fr)
NZ (1) NZ242813A (fr)
PT (1) PT100511A (fr)
WO (1) WO1992020365A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE140966T1 (de) * 1990-09-25 1996-08-15 Genentech Inc Neuer neurotropischer faktor
ATE154389T1 (de) 1991-02-18 1997-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von menschlichem ngf-2
WO1993025684A1 (fr) * 1992-06-12 1993-12-23 Regeneron Pharmaceuticals, Inc. Procedes therapeutique et diagnostique bases sur l'expression de la neurotrophine-4
FI991197A0 (fi) * 1999-05-27 1999-05-27 Mart Saarma Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
ATE140966T1 (de) * 1990-09-25 1996-08-15 Genentech Inc Neuer neurotropischer faktor
IL101661A (en) * 1991-04-23 1998-02-08 Regeneron Pharma Method for detecting, identifying or measuring agents having neurotrophin activity

Also Published As

Publication number Publication date
JPH08510987A (ja) 1996-11-19
PT100511A (pt) 1993-09-30
NZ242813A (en) 1996-09-25
AU2302192A (en) 1992-12-30
WO1992020365A1 (fr) 1992-11-26
IE921636A1 (en) 1992-12-02
EP0587806A1 (fr) 1994-03-23
EP0587806A4 (fr) 1995-04-26
AU674659B2 (en) 1997-01-09

Similar Documents

Publication Publication Date Title
Goodearl et al. ARIA is concentrated in the synaptic basal lamina of the developing chick neuromuscular junction.
EP2107109B1 (fr) Facteur D recombinant de croissance de cellules vasculaires endotheliales
CA2040437C (fr) Neurotrophine-3, nouveau facteur neurotrophique lie au facteur de croissance du tissu nerveux et au facteur neurotrophique derive du cerveau
US5229500A (en) Brain derived neurotrophic factor
HK1006578B (en) Brain derived neurotrophic factor
EP0542892A1 (fr) Facteurs neurotrophiques chimeriques
EP0644937A4 (en) Therapeutic and diagnostic methods based on neurotrophin-4 expression.
AU758011B2 (en) Persephin and related growth factors
CA2109598A1 (fr) Methodes therapeutiques et diagnostiques basees sur l'expression de la neurotrophine 4
US6933276B1 (en) Methods of treating peripheral neuropathies using neurotrophin-3
JP2001527418A (ja) グリア細胞系由来の神経栄養因子レセプター
WO1994009765A1 (fr) Interactions fonctionnelles entre le s-100b glial et les neurones serotoninergiques du systeme nerveux central
NZ270485A (en) Diagnosis of motor neuron disease using neurotrophin-4 (nt-4) and methods for measuring its activity
HK1025789B (en) Recombinant vascular endothelial cell growth factor d (vegf-d)
MXPA99010773A (en) Glial cell line-derived neurotrophic factor receptors

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19990520